

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Cancelled).
2. (Cancelled).
3. (Previously presented) The mixture according to Claim 10, wherein the polypropylene glycol moiety has at least 5 polypropylene glycol subunits.
4. (Previously presented) The mixture according to Claim 10, wherein the polypropylene glycol moiety has at least 7 polypropylene glycol subunits.
5. (Previously presented) The mixture according to Claim 10, wherein the oligomer is covalently coupled to the drug.
6. (Previously presented) The mixture according to Claim 10, wherein the oligomer further comprises a lipophilic moiety.
7. (Cancelled).
8. (Cancelled).
9. (Cancelled).
10. (Previously presented) A substantially monodispersed mixture of conjugates, each conjugate comprising a drug coupled to an oligomer that comprises a polypropylene glycol moiety having at least 2 polypropylene glycol subunits.
11. (Original) The mixture according to Claim 10, wherein the polypropylene glycol moiety is uniform.

12. (Original) The mixture according to Claim 11, wherein the oligomer is devoid of a lipophilic moiety, and wherein the conjugate is amphiphilically balanced such that it is aqueously soluble and able to penetrate biological membranes.

13. (Previously presented) The mixture according to Claim 10, wherein at least 96 percent of the conjugates in the mixture have the same molecular weight.

14. (Previously presented) The mixture according to Claim 10, wherein the mixture is a monodispersed mixture.

15. (Previously presented) The mixture according to Claim 10, wherein the mixture is a substantially purely monodispersed mixture.

16. (Previously presented) The mixture according to Claim 10, wherein at least 96 percent of the conjugates in the mixture have the same molecular weight and the same molecular structure.

17. (Previously presented) The mixture according to Claim 10, wherein the mixture is a purely monodispersed mixture.

18. (Original) The mixture according to Claim 17, wherein the oligomer is covalently coupled to the drug.

19. (Original) The mixture according to Claim 17, wherein the oligomer further comprises a lipophilic moiety.

20. (Cancelled).

21. (Cancelled).

22. (Cancelled).

23. (Cancelled).

24. (Previously presented) The mixture according to Claim 17, wherein the polypropylene glycol moiety is uniform.

25. (Original) The mixture according to Claim 24, wherein the oligomer is devoid of a lipophilic moiety, and wherein the conjugate is amphiphilically balanced such that it is aqueously soluble and able to penetrate biological membranes.

26. (Previously presented) The mixture according to Claim 10, wherein the mixture has an *in vivo* activity that is greater than the *in vivo* activity of a polydispersed mixture of drug-oligomer conjugates having the same number average molecular weight as the mixture.

27. (Previously presented) The mixture according to Claim 10, wherein the mixture has an *in vitro* activity that is greater than the *in vitro* activity of a polydispersed mixture of drug-oligomer conjugates having the same number average molecular weight as the mixture.

28. (Previously presented) The mixture according to Claim 10, wherein the mixture has an increased resistance to degradation by chymotrypsin when compared to the resistance to degradation by chymotrypsin of a polydispersed mixture of drug-oligomer conjugates having the same number average molecular weight as the mixture.

29. (Previously presented) The mixture according to Claim 10, wherein the mixture has an inter-subject variability that is less than the inter-subject variability of a polydispersed mixture of drug-oligomer conjugates having the same number average molecular weight as the mixture.

30. (Previously presented) The mixture according to Claim 10, wherein the drug is a polypeptide.

31. (Original) The mixture according to Claim 30, wherein the polypeptide is selected from the group consisting of adrenocorticotrophic hormone peptides, adrenomedullin peptides, allatostatin peptides, amylin peptides, amyloid beta-protein fragment peptides, angiotensin peptides, antibiotic peptides, antigenic polypeptides, anti-microbial peptides, apoptosis related peptides, atrial natriuretic peptides, bag cell peptides, bombesin peptides, bone GLA peptides, bradykinin peptides, brain natriuretic peptides, C-peptides, C-type natriuretic peptides, calcitonin peptides, calcitonin gene related

peptides, CART peptides, casomorphin peptides, chemotactic peptides, cholecystokinin peptides, colony-stimulating factor peptides, corticotropin releasing factor peptides, cortistatin peptides, cytokine peptides, dermorphin peptides, dynorphin peptides, endorphin peptides, endothelin peptides, ET<sub>a</sub> receptor antagonist peptides, ET<sub>b</sub> receptor antagonist peptides, enkephalin peptides, fibronectin peptides, galanin peptides, gastrin peptides, glucagon peptides, Gn-RH associated peptides, growth factor peptides, growth hormone peptides, GTP-binding protein fragment peptides, guanylin peptides, inhibin peptides, insulin peptides, interleukin peptides, laminin peptides, leptin peptides, leucokinin peptides, luteinizing hormone-releasing hormone peptides, mastoparan peptides, mast cell degranulating peptides, melanocyte stimulating hormone peptides, morphiceptin peptides, motilin peptides, neuro-peptides, neuropeptide Y peptides, neurotropic factor peptides, orexin peptides, opioid peptides, oxytocin peptides, PACAP peptides, pancreastatin peptides, pancreatic polypeptides, parathyroid hormone peptides, parathyroid hormone-related peptides, peptide T peptides, prolactin-releasing peptides, peptide YY peptides, renin substrate peptides, secretin peptides, somatostatin peptides, substance P peptides, tachykinin peptides, thyrotropin-releasing hormone peptides, toxin peptides, vasoactive intestinal peptides, vasopressin peptides, and virus related peptides.

32. (Original) The mixture according to Claim 30, wherein the oligomer is covalently coupled to a nucleophilic residue of the polypeptide.

33. (Cancelled).

34. (Cancelled).

35. (Cancelled).

36. (Cancelled).

37. (Cancelled).

38. (Previously presented) The mixture according to Claim 39, wherein the polypropylene glycol moiety is uniform.

39. (Previously presented) A substantially monodispersed mixture of conjugates, each conjugate comprising a drug coupled to an oligomer that comprises a polypropylene glycol moiety and wherein the oligomer is devoid of a lipophilic moiety, and wherein the conjugate is amphiphilically balanced such that it is aqueously soluble and able to penetrate biological membranes.

40. (Previously presented) The mixture according to Claim 39, wherein the oligomer is covalently coupled to the drug.

41. (Cancelled).

42. (Cancelled).

43 (Cancelled).

44. (Cancelled).

45. (Cancelled).

46. (Previously presented) The mixture according to Claim 39, wherein the polypropylene glycol moiety is uniform.

47. (Cancelled).

48. (Previously presented) The mixture according to Claim 10, wherein each conjugate comprises a plurality of oligomers.

49. (Original) The mixture according to Claim 48, wherein each oligomer in the plurality of oligomers is the same.

50. (Previously presented) The mixture according to Claim 10, wherein the oligomer comprises a first polypropylene glycol moiety covalently coupled to the drug by a non-hydrolyzable bond and a second polypropylene glycol moiety covalently coupled to the first polypropylene glycol moiety by a hydrolyzable bond.

51. (Previously presented) The mixture according to Claim 50, wherein the oligomer further comprises a lipophilic moiety covalently coupled to the second polypropylene glycol moiety.

52. (Cancelled).

53. (Previously presented) A pharmaceutical composition comprising:  
the mixture according to Claim 10; and  
a pharmaceutically acceptable carrier.

54. (Cancelled).

55. (Previously presented) The mixture according to Claim 61, wherein the standard deviation of the molecular weight distribution is less than about 14 Daltons.

56. (Previously presented) The mixture according to Claim 61, wherein the standard deviation of the molecular weight distribution is less than about 11 Daltons.

57. (Cancelled).

58. (Previously presented) The mixture according to Claim 61, wherein the polypropylene glycol moiety has at least 7 polypropylene glycol subunits.

59. (Cancelled).

60. (Previously presented) The mixture according to Claim 61, wherein the oligomer further comprises a lipophilic moiety.

61. (Previously presented) A mixture of conjugates each comprising a drug coupled to an oligomer that comprises a polypropylene glycol moiety, said mixture having a molecular weight distribution with a standard deviation of less than about 22 Daltons.

62. (Original) The mixture according to Claim 61, wherein the polypropylene glycol moiety is uniform.

63. (Original) The mixture according to Claim 62, wherein the oligomer is devoid of a lipophilic moiety, and wherein the conjugate is amphiphilically balanced such that it is aqueously soluble and able to penetrate biological membranes.

64. (Previously presented) The mixture according to Claim 61, wherein the drug is a polypeptide selected from the group consisting of adrenocorticotrophic hormone peptides, adrenomedullin peptides, allatostatin peptides, amylin peptides, amyloid beta-protein fragment peptides, angiotensin peptides, antibiotic peptides, antigenic polypeptides, anti-microbial peptides, apoptosis related peptides, atrial natriuretic peptides, bag cell peptides, bombesin peptides, bone GLA peptides, bradykinin peptides, brain natriuretic peptides, C-peptides, C-type natriuretic peptides, calcitonin peptides, calcitonin gene related peptides, CART peptides, casomorphin peptides, chemotactic peptides, cholecystokinin peptides, colony-stimulating factor peptides, corticotropin releasing factor peptides, cortistatin peptides, cytokine peptides, dermorphin peptides, dynorphin peptides, endorphin peptides, endothelin peptides, ET<sub>a</sub> receptor antagonist peptides, ET<sub>b</sub> receptor antagonist peptides, enkephalin peptides, fibronectin peptides, galanin peptides, gastrin peptides, glucagon peptides, Gn-RH associated peptides, growth factor peptides, growth hormone peptides, GTP-binding protein fragment peptides, guanylin peptides, inhibin peptides, insulin peptides, interleukin peptides, laminin peptides, leptin peptides, leucokinin peptides, luteinizing hormone-releasing hormone peptides, mastoparan peptides, mast cell degranulating peptides, melanocyte stimulating hormone peptides, morphiceptin peptides, motilin peptides, neuro-peptides, neuropeptide Y peptides, neurotropic factor peptides, orexin peptides, opioid peptides, oxytocin peptides, PACAP peptides, pancreastatin peptides, pancreatic polypeptides, parathyroid hormone peptides, parathyroid hormone-related peptides, peptide T peptides, prolactin-releasing peptides, peptide YY peptides, renin substrate peptides, secretin peptides, somatostatin peptides, substance P peptides, tachykinin peptides, thyrotropin-releasing hormone peptides, toxin peptides, vasoactive intestinal peptides, vasopressin peptides, and virus related peptides.

65. (Cancelled).

66. (Previously presented) The mixture according to Claim 72, wherein the dispersity coefficient is greater than 100,000.

67. (Previously presented) The mixture according to Claim 72, wherein the dispersity coefficient is greater than 500,000.

68. (Cancelled).

69. (Currently amended) The mixture according to Claim 72, wherein the ~~lower alkyl polyalkylene polypropylene glycol~~ moiety has at least 7 ~~polyalkylene polypropylene glycol~~ subunits.

70. (Cancelled).

71. (Currently Amended) The mixture according to Claim 72, wherein the ~~oligomer polymer~~ further comprises a lipophilic moiety.

72. (Previously presented) A mixture of conjugates each comprising a drug coupled to a polymer comprising a polypropylene glycol moiety, wherein the mixture has a dispersity coefficient (DC) greater than 10,000 where

$$DC = \frac{\left( \sum_{i=1}^n N_i M_i \right)^2}{\sum_{i=1}^n N_i M_i^2 \sum_{i=1}^n N_i - \left( \sum_{i=1}^n N_i M_i \right)^2}$$

wherein:

n is the number of different molecules in the sample;

$N_i$  is the number of  $i^{\text{th}}$  molecules in the sample; and

$M_i$  is the mass of the  $i^{\text{th}}$  molecule.

73. (Original) The mixture according to Claim 72, wherein the polypropylene glycol moiety is uniform.

74. (Currently Amended) The mixture according to Claim 73, wherein the ~~oligomer polymer~~ is devoid of a lipophilic moiety, and wherein the conjugate is amphiphilically balanced such that it is aqueously soluble and able to penetrate biological membranes.

75. (Previously presented) The mixture according to Claim 72, wherein the drug is a polypeptide selected from the group consisting of adrenocorticotrophic hormone peptides, adrenomedullin peptides, allatostatin peptides, amylin peptides, amyloid beta-protein fragment peptides, angiotensin peptides, antibiotic peptides, antigenic polypeptides, anti-microbial peptides, apoptosis related peptides, atrial natriuretic peptides, bag cell peptides, bombesin peptides, bone GLA peptides, bradykinin peptides, brain natriuretic peptides, C-peptides, C-type natriuretic peptides, calcitonin peptides, calcitonin gene related peptides, CART peptides, casomorphin peptides, chemotactic peptides, cholecystokinin peptides, colony-stimulating factor peptides, corticotropin releasing factor peptides, cortistatin peptides, cytokine peptides, dermorphin peptides, dynorphin peptides, endorphin peptides, endothelin peptides, ET<sub>a</sub> receptor antagonist peptides, ET<sub>b</sub> receptor antagonist peptides, enkephalin peptides, fibronectin peptides, galanin peptides, gastrin peptides, glucagon peptides, Gn-RH associated peptides, growth factor peptides, growth hormone peptides, GTP-binding protein fragment peptides, guanylin peptides, inhibin peptides, insulin peptides, interleukin peptides, laminin peptides, leptin peptides, leucokinin peptides, luteinizing hormone-releasing hormone peptides, mastoparan peptides, mast cell degranulating peptides, melanocyte stimulating hormone peptides, morphiceptin peptides, motilin peptides, neuro-peptides, neuropeptide Y peptides, neurotropic factor peptides, orexin peptides, opioid peptides, oxytocin peptides, PACAP peptides, pancreastatin peptides, pancreatic polypeptides, parathyroid hormone peptides, parathyroid hormone-related peptides, peptide T peptides, prolactin-releasing peptides, peptide YY peptides, renin substrate peptides, secretin peptides, somatostatin peptides, substance P peptides, tachykinin peptides, thyrotropin-releasing hormone peptides, toxin peptides, vasoactive intestinal peptides, vasopressin peptides, and virus related peptides.

76. (Cancelled).

77. (Cancelled).

78. (Previously presented) The mixture according to Claim 81, wherein the polypropylene glycol moiety has at least 7 polypropylene glycol subunits.

79. (Cancelled).

80. (Previously presented) The mixture according to Claim 81, wherein the oligomer further comprises a lipophilic moiety.


81. (Previously presented) A mixture of conjugates in which each conjugate: comprises a drug coupled to an oligomer; and has the same number of polypropylene glycol subunits.

82. (Original) The mixture according to Claim 81, wherein the polypropylene glycol moiety is uniform.

83. (Original) The mixture according to Claim 82, wherein the oligomer is devoid of a lipophilic moiety, and wherein the conjugate is amphiphilically balanced such that it is aqueously soluble and able to penetrate biological membranes.

84. (Previously presented) The mixture according to Claim 81, wherein the drug is a polypeptide selected from the group consisting of adrenocorticotropic hormone peptides, adrenomedullin peptides, allatostatin peptides, amylin peptides, amyloid beta-protein fragment peptides, angiotensin peptides, antibiotic peptides, antigenic polypeptides, anti-microbial peptides, apoptosis related peptides, atrial natriuretic peptides, bag cell peptides, bombesin peptides, bone GLA peptides, bradykinin peptides, brain natriuretic peptides, C-peptides, C-type natriuretic peptides, calcitonin peptides, calcitonin gene related peptides, CART peptides, casomorphin peptides, chemotactic peptides, cholecystokinin peptides, colony-stimulating factor peptides, corticotropin releasing factor peptides, cortistatin peptides, cytokine peptides, dermorphin peptides, dynorphin peptides, endorphin peptides, endothelin peptides, ET<sub>a</sub> receptor antagonist peptides, ET<sub>b</sub> receptor antagonist peptides, enkephalin peptides, fibronectin peptides, galanin peptides, gastrin peptides, glucagon peptides, Gn-RH associated peptides, growth factor peptides, growth hormone peptides, GTP-binding protein fragment peptides, guanylin peptides, inhibin peptides, insulin peptides, interleukin peptides, laminin peptides, leptin peptides, leucokinin peptides, luteinizing hormone-releasing hormone peptides, mastoparan peptides, mast cell degranulating peptides, melanocyte stimulating hormone peptides, morphiceptin peptides, motilin peptides, neuro-peptides, neuropeptide Y peptides, neurotropic factor peptides, orexin peptides, opioid peptides, oxytocin peptides, PACAP peptides, pancreastatin peptides, pancreatic polypeptides, parathyroid hormone peptides, parathyroid hormone-related peptides, peptide T peptides, prolactin-releasing peptides, peptide YY peptides, renin substrate peptides, secretin peptides, somatostatin peptides, substance P peptides, tachykinin peptides, thyrotropin-releasing hormone peptides, toxin peptides, vasoactive intestinal peptides, vasopressin peptides, and virus related peptides.

85. (Currently amended) A mixture of conjugates in which each conjugate has the same molecular weight and has the formula:



wherein:

B is a bonding moiety;

L is a linker moiety;

G, G' and G" are individually selected spacer moieties;

R is a lipophilic moiety and R' is a polypropylene glycol moiety, or R' is the a lipophilic moiety and R is the a polypropylene glycol moiety;

T is a terminating moiety;

h, i, j, k, m and n are individually 0 or 1, with the proviso that when R is the polyalkylene a polypropylene glycol moiety, m is 1; and when R' is the polyalkylene a polypropylene glycol moiety, n is 1; and

p is an integer from 1 to the number of nucleophilic residues on the drug.

86. (Cancelled).

87. (Previously presented) The mixture according to Claim 85, wherein the polypropylene glycol moiety has at least 7 polypropylene glycol subunits.

88. (Cancelled).

89. (Previously presented) The mixture according to Claim 85, wherein:

R is the polypropylene glycol moiety;

R' is a lipophilic moiety;

n and m are 1; and

i, j and k are 0.

90. (Previously presented) The mixture according to Claim 85, wherein:

R is a lipophilic moiety;

R' is the polypropylene glycol moiety;

n and m are 1; and

i, j and k are each 0.

91. (Cancelled).

92. (Previously presented) The mixture according to Claim 85, wherein the polypropylene glycol moiety is uniform.

93. (Original) The mixture according to Claim 92, wherein:

R is the polypropylene glycol moiety;

m is 1;

i, j, k and n are each 0; and

each conjugate in the mixture is amphiphilically balanced such that each conjugate is aqueously soluble and able to penetrate biological membranes.


94. (Original) The mixture according to Claim 85, wherein the drug is a polypeptide selected from the group consisting of adrenocorticotropic hormone peptides, adrenomedullin peptides, allatostatin peptides, amylin peptides, amyloid beta-protein fragment peptides, angiotensin peptides, antibiotic peptides, antigenic polypeptides, anti-microbial peptides, apoptosis related peptides, atrial natriuretic peptides, bag cell peptides, bombesin peptides, bone GLA peptides, bradykinin peptides, brain natriuretic peptides, C-peptides, C-type natriuretic peptides, calcitonin peptides, calcitonin gene related peptides, CART peptides, casomorphin peptides, chemotactic peptides, cholecystokinin peptides, colony-stimulating factor peptides, corticotropin releasing factor peptides, cortistatin peptides, cytokine peptides, dermorphin peptides, dynorphin peptides, endorphin peptides, endothelin peptides, ET<sub>a</sub> receptor antagonist peptides, ET<sub>b</sub> receptor antagonist peptides, enkephalin peptides, fibronectin peptides, galanin peptides, gastrin peptides, glucagon peptides, Gn-RH associated peptides, growth factor peptides, growth hormone peptides, GTP-binding protein fragment peptides, guanylin peptides, inhibin peptides, insulin peptides, interleukin peptides, laminin peptides, leptin peptides, leucokinin peptides, luteinizing hormone-releasing hormone peptides, mastoparan peptides, mast cell degranulating peptides, melanocyte stimulating hormone peptides, morphiceptin peptides, motilin peptides, neuro-peptides, neuropeptide Y peptides, neurotropic factor peptides, orexin peptides, opioid peptides, oxytocin peptides, PACAP peptides, pancreastatin peptides, pancreatic polypeptides, parathyroid hormone peptides, parathyroid hormone-related peptides, peptide T peptides, prolactin-releasing peptides, peptide YY peptides, renin substrate peptides, secretin peptides, somatostatin peptides, substance P peptides, tachykinin peptides,

thyrotropin-releasing hormone peptides, toxin peptides, vasoactive intestinal peptides, vasopressin peptides, and virus related peptides.

95. (Cancelled).

96. (Previously presented) A process for synthesizing a substantially monodispersed mixture of conjugates each conjugate comprising a drug coupled to an oligomer that comprises a polyethylene glycol moiety, said process comprising:

reacting a substantially monodispersed mixture comprising compounds having the structure of Formula I:



wherein  $R^1$  is H or a lipophilic moiety; m is from 1 to 25; and  $X^+$  is a positive ion, with a substantially monodispersed mixture comprising compounds having the structure of Formula II:



wherein  $R^2$  is a fatty acid moiety or an ester of a fatty acid moiety; and n is from 1 to 25,

under conditions sufficient to provide a substantially monodispersed mixture comprising polymers having the structure of Formula III:




activating the substantially monodispersed mixture comprising polymers of Formula III to provide a substantially monodispersed mixture of activated polymers capable of reacting with a drug; and

reacting the substantially monodispersed mixture of activated polymers with a drug under conditions sufficient to provide a substantially monodispersed mixture of conjugates each comprising a drug coupled to an oligomer that comprises a polyethylene glycol moiety with  $m+n$  subunits.

97. (Original) The process according to Claim 96, wherein the fatty acid moiety or the ester of a fatty acid moiety comprises an alkyl moiety at least 5 carbon atoms in length.

98. (Previously presented) The process according to Claim 96, wherein R<sup>1</sup> is a methyl group.

99. (Currently amended) The process according to Claim 96, further comprising:  
reacting a substantially monodispersed mixture comprising compounds having the structure of Formula V:



with a methanesulfonyl halide under conditions sufficient to provide a substantially monodispersed mixture comprising compounds having the structure of Formula II:




100. (Currently Amended) The process according to Claim 96, further comprising A process for synthesizing a substantially monodispersed mixture of conjugates each conjugate comprising a drug coupled to an oligomer that comprises a polyethylene glycol moiety, said process comprising:

reacting a substantially monodispersed mixture comprising compounds having the structure of Formula VI:



wherein R<sup>2</sup> is a lipophilic moiety;

with a substantially monodispersed mixture comprising compounds having the structure of Formula VII:



wherein R<sup>3</sup> is benzyl, trityl, or THP; and X<sub>2</sub><sup>+</sup> is a positive ion;

under conditions sufficient to provide a substantially monodispersed mixture comprising compounds having the structure of Formula VIII:




reacting the substantially monodispersed mixture comprising compounds having the structure of Formula VIII under conditions sufficient to provide a substantially monodispersed mixture comprising compounds having the structure of Formula V:



reacting the substantially monodispersed mixture comprising compounds having the structure of Formula V;


with a methanesulfonyl halide comprising compounds having the structure  $\text{CH}_3\text{SO}_2\text{Q}$ , wherein Q is a halide;

under conditions sufficient to provide a substantially monodispersed mixture comprising compounds having the structure of Formula II:



wherein  $\text{R}^2$  is a lipophilic moiety; and n is from 1 to 25;

reacting a substantially monodispersed mixture comprising compounds having the structure of Formula I:



wherein  $\text{R}^1$  is H or a lipophilic moiety; m is from 1 to 25; and  $\text{X}^+$  is a positive ion.

with the substantially monodispersed mixture comprising compounds having the structure of Formula II,

under conditions sufficient to provide a substantially monodispersed mixture comprising polymers having the structure of Formula III:



activating the substantially monodispersed mixture comprising polymers of Formula III to provide a substantially monodispersed mixture of activated polymers capable of reacting with a drug; and


reacting the substantially monodispersed mixture of activated polymers with a drug under conditions sufficient to provide a substantially monodispersed mixture of conjugates each comprising a drug coupled to an oligomer that comprises a polyethylene glycol moiety with  $m+n$  subunits.

101. (Previously presented) The process according to Claim 96, further comprising:

reacting a substantially monodispersed mixture comprising compounds having the structure of Formula IV:



under conditions sufficient to provide a substantially monodispersed mixture comprising compounds having the structure of Formula I:



102. (Previously presented) The process according to Claim 96, wherein the activating of the substantially monodispersed mixture comprises reacting the substantially monodispersed mixture of polymers of Formula III with N-hydroxy succinimide to provide an activated polymer capable of reacting with a drug.

103. (Previously presented) The process according to Claim 96, wherein the drug is a polypeptide, and wherein the reacting of the substantially monodispersed mixture of activated polymers with a substantially monodispersed mixture of polypeptides comprises:

reacting the substantially monodispersed mixture of activated polymers with one or more amino functionalities of the polypeptide to provide a substantially monodispersed mixture of conjugates each comprising the polypeptide coupled to an oligomer that comprises a polyethylene glycol moiety with  $m+n$  subunits.

104. (Cancelled).

105. (Previously presented) A pharmaceutical composition comprising:  
the mixture according to Claim 17; and  
pharmaceutically acceptable carrier.

106. (Previously presented) A pharmaceutical composition comprising:  
the mixture according to Claim 39; and  
a pharmaceutically acceptable carrier.

107. (Previously presented) A pharmaceutical composition comprising:  
the mixture according to Claim 61; and

a pharmaceutically acceptable carrier.

108. (Previously presented) A pharmaceutical composition comprising:

the mixture according to Claim 72; and

a pharmaceutically acceptable carrier.

109. (Previously presented) A pharmaceutical composition comprising:

the mixture according to Claim 81; and

a pharmaceutically acceptable carrier.

110. (Previously presented) A pharmaceutical composition comprising:

the mixture according to Claim 85; and

a pharmaceutically acceptable carrier.